Calithera Biosciences, Inc. (CALA)
| Market Cap | 148.10M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -86.09M |
| Shares Out | 72.25M |
| EPS (ttm) | -1.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 29 |
| Last Price | $1.97 |
| Previous Close | $2.00 |
| Change ($) | -0.03 |
| Change (%) | -1.50% |
| Day's Open | 2.00 |
| Day's Range | 1.96 - 2.02 |
| Day's Volume | 145,394 |
| 52-Week Range | 1.78 - 6.19 |
Investors need to pay close attention to Calithera Biosciences (CALA) stock based on the movements in the options market lately.
SOUTH SAN FRANCISCO, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small-molecu...
SHANGHAI and SOUTH SAN FRANCISCO, Calif., May 17, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering...
SOUTH SAN FRANCISCO, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molec...
SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small-molec...
--Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on March 16, 2021-- SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (N...
SOUTH SAN FRANCISCO, Calif., March 12, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molec...
SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molec...
Investors need to pay close attention to Calithera Biosciences (CALA) stock based on the movements in the options market lately.
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecu...
Calithera (CALA) tanks as CANTATA study on its lead pipeline candidate, telaglenastat, did not achieve its primary goal for RCC.
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecu...
Calithera Biosciences (NASDAQ: CALA) shares are trading lower after the company announced that its CANTATA study of Telaglenastat in Renal Cell Carcinoma did not achieve its primary endpoint. The compan...
The company reported negative results from a clinical trial.
-- Company will continue to advance telaglenastat KEAPSAKE trial in non-small cell lung cancer, arginase inhibitor CB-280 trial in cystic fibrosis and emerging pipeline
Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecu...
Investors need to pay close attention to Calithera (CALA) stock based on the movements in the options market lately.
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecu...
Calithera has an important near-term catalyst that could launch the company into a significant commercialization opportunity by mid-year 2021. The company also is running a triplet therapy trial that if...
Calithera to Participate in Jefferies Virtual Healthcare Conference and SVB Leerink Oncology 1x1 Day
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecu...
IL4I1 inhibitor shows immune-mediated anti-tumor activity IL4I1 inhibitor shows immune-mediated anti-tumor activity
Calithera Biosciences' (CALA) CEO Susan Molineaux on Q3 2020 Results - Earnings Call Transcript
--Calithera to Provide Corporate Update via Conference Call and Webcast at2:00 p.m. PT on November 5, 2020-- SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (N...
Combination will be evaluated in patients with pancreatic ductal adenocarcinoma whose tumors have KRAS and CDKN2A mutations Combination will be evaluated in patients with pancreatic ductal adenocarcinom...
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small-molecu...
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecu...
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small-molecu...
Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecu...
- Study will evaluate safety and efficacy of glutaminase inhibition in combination with standard - of - care treatment in front-line setting among patients with non-small cell lung cancer and a m...
SOUTH SAN FRANCISCO, Calif., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small mol...
Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q2 2020 Results - Earnings Call Transcript
Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q2 2020 Results - Earnings Call Transcript
--Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on August 10, 2020-- SOUTH SAN FRANCISCO, Calif., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. ...
SOUTH SAN FRANCISCO, Calif., July 28, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small mole...
Former Portola Pharmaceuticals President and Chief Executive Officer Brings Extensive Executive Leadership and Commercial Oncology Experience Former Portola Pharmaceuticals President and Chief Executive...
SOUTH SAN FRANCISCO, July 13, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule dru...
SOUTH SAN FRANCISCO, Calif., July 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small mole...
SOUTH SAN FRANCISCO, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small mole...
SOUTH SAN FRANCISCO, Calif., May 29, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small-molec...
Is (CALA) Outperforming Other Medical Stocks This Year?
Calithera Biosciences (CALA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Calithera (CALA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q1 2020 Results - Earnings Call Transcript
Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q1 2020 Results - Earnings Call Transcript
-- KEAPSAKE is a Phase 2 randomized trial exploring telaglenastat with standard of care in first-line treatment of patients with lung cancer with KEAP1/NRF2 mutations -- KEAPSAKE is a Phase 2 randomized...
SOUTH SAN FRANCISCO, Calif., April 20, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small mol...
SOUTH SAN FRANCISCO, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small mol...
SOUTH SAN FRANCISCO, Calif., April 15, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small mol...
Calithera (CALA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
SOUTH SAN FRANCISCO, April 14, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small-molecule dr...
Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q4 2019 Results - Earnings Call Transcript
Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q4 2019 Results - Earnings Call Transcript
SOUTH SAN FRANCISCO, Calif., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small mole...
About CALA
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also dev... [Read more...]
| Industry Biotechnology | IPO Date Oct 2, 2014 |
| CEO Susan Molineaux | Employees 92 |
| Stock Exchange NASDAQ | Ticker Symbol CALA |
Analyst Forecasts
According to 6 analysts, the average rating for CALA stock is "Buy." The 12-month stock price forecast is 5.00, which is an increase of 153.81% from the latest price.